VA
ARTV

VR Adviser’s Artiva Biotherapeutics ARTV Stock Holding History

VR Adviser’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Hold
1,609,569
– – 0.39% 32
2025
Q4 		$6.91M Hold
1,609,569
– – 0.34% 26
2025
Q3 		$4.62M Hold
1,609,569
– – 0.26% 31
2025
Q2 		$2.43M Hold
1,609,569
– – 0.18% 29
2025
Q1 		$4.83M Hold
1,609,569
– – 0.41% 27
2024
Q4 		$16.2M Hold
1,609,569
– – 1.11% 22
2024
Q3 		$24.9M Buy
+1,609,569
New +$18.7M 1.3% 22

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser's ARTV Position: Q1 2026 in Review

VR Adviser held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 1,609,569 shares worth $10.4M. The position accounts for 0.39% of the portfolio, ranked #32.

VR Adviser first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $24.9M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • VR Adviser held 1,609,569 shares of Artiva Biotherapeutics worth $10.4M as of Q1 2026.
  • VR Adviser left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up 0.39% of VR Adviser's portfolio in Q1 2026, its #32 holding.
  • VR Adviser first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • VR Adviser's Artiva Biotherapeutics position peaked at $24.9M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.